Literature DB >> 9155049

Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression.

G Fontanini1, S Vignati, M Lucchi, A Mussi, A Calcinai, L Boldrini, S Chiné, V Silvestri, C A Angeletti, F Basolo, G Bevilacqua.   

Abstract

Following up-regulation of an angiogenesis inhibitor by the wild-type p53 protein proven recently, we have analysed on the one hand the prognostic impact of microvessel count (MC) and p53 protein overexpression in non-small-cell lung carcinoma (NSCLC) progression and, on the other hand, the inter-relation between the microvascular pattern and the p53 protein expression. Moreover, we assessed the expression of vascular endothelial growth factor (VEGF), one of the pivotal mediators of tumour angiogenesis, in order to investigate its relation to p53 protein expression and MC. Tumours from 73 patients resected for NSCLC between March 1991 and April 1992 (median follow-up 47 months, range 32-51 months) were analysed using an immunohistochemical method. In univariate analysis, MC and p53 accumulation were shown to affect metastatic nodal involvement, recurrence and death significantly. Multiple logistic regression analysis showed an important prognostic influence of MC and nodal status on overall (P = 0.0009; P = 0.01) and disease-free survival (P = 0.0001; P = 0.03). Interestingly, a strong statistical association was observed between p53 nuclear accumulation and MC (P = 0.0003). The same inter-relationship was found in non-squamous histotype (P = 0.002). When we analysed the concomitant influence of MC and p53 expression on overall survival, we were able to confirm a real predominant role of MC in comparison with p53. With regard to VEGF expression, p53-negative and lowly vascularized tumours showed a mean VEGF expression significantly lower than p53-positive and highly vascularized cancers (P = 0.02). These results underline the prognostic impact of MC and p53 protein accumulation in NSCLC and their reciprocal inter-relationship, supporting the hypothesis of a wild-type p53 regulation on the angiogenetic process through a VEGF up-regulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9155049      PMCID: PMC2228220          DOI: 10.1038/bjc.1997.220

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  DMPA, zalcitabine, and the FDA.

Authors: 
Journal:  Lancet       Date:  1992-07-04       Impact factor: 79.321

2.  Deletions of 17p and p53 mutations in preneoplastic lesions of the lung.

Authors:  G Sozzi; M Miozzo; R Donghi; S Pilotti; C T Cariani; U Pastorino; G Della Porta; M A Pierotti
Journal:  Cancer Res       Date:  1992-11-01       Impact factor: 12.701

3.  Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene.

Authors:  F Rastinejad; P J Polverini; N P Bouck
Journal:  Cell       Date:  1989-02-10       Impact factor: 41.582

Review 4.  A new international staging system for lung cancer.

Authors:  C F Mountain
Journal:  Chest       Date:  1986-04       Impact factor: 9.410

5.  Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma.

Authors:  M Tateishi; T Ishida; T Mitsudomi; S Kaneko; K Sugimachi
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

6.  Expression of blood-group antigen A--a favorable prognostic factor in non-small-cell lung cancer.

Authors:  J S Lee; J Y Ro; A A Sahin; W K Hong; B W Brown; C F Mountain; W N Hittelman
Journal:  N Engl J Med       Date:  1991-04-18       Impact factor: 91.245

7.  The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer.

Authors:  G Fontanini; P Macchiarini; S Pepe; A Ruggiero; M Hardin; D Bigini; S Vignati; R Pingitore; C A Angeletti
Journal:  Cancer       Date:  1992-09-15       Impact factor: 6.860

8.  Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma.

Authors:  R L Barnhill; K Fandrey; M A Levy; M C Mihm; B Hyman
Journal:  Lab Invest       Date:  1992-09       Impact factor: 5.662

9.  p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus.

Authors:  V Sundaresan; P Ganly; P Hasleton; R Rudd; G Sinha; N M Bleehen; P Rabbitts
Journal:  Oncogene       Date:  1992-10       Impact factor: 9.867

10.  Accumulation of p53 protein correlates with a poor prognosis in human lung cancer.

Authors:  D C Quinlan; A G Davidson; C L Summers; H E Warden; H M Doshi
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

View more
  21 in total

1.  Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.

Authors:  O Straume; L A Akslen
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  A three-dimensional analysis of blood vessels in bronchioloalveolar carcinoma.

Authors:  Takeshi Uehara; Takayuki Honda; Kenji Sano; Tsutomu Hachiya; Hiroyoshi Ota
Journal:  Lung       Date:  2004       Impact factor: 2.584

3.  Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer.

Authors:  R Baillie; J Carlile; N Pendleton; A M Schor
Journal:  J Clin Pathol       Date:  2001-02       Impact factor: 3.411

4.  bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer.

Authors:  M I Koukourakis; A Giatromanolaki; K J O'Byrne; J Cox; B Krammer; K C Gatter; A L Harris
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

Review 5.  Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients.

Authors:  Denisa Baci; Elona Cekani; Andrea Imperatori; Domenico Ribatti; Lorenzo Mortara
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

6.  p53 and angiogenesis in non-small-cell lung cancer.

Authors:  A Giatromanolaki; M I Koukourakis
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

7.  VEGF expression and its reguration by p53 gene transfection in endometrial carcinoma cells.

Authors:  T Fujisawa; J Watanabe; Y Kamata; M Hamano; H Hata; H Kuramoto
Journal:  Hum Cell       Date:  2003-03       Impact factor: 4.174

Review 8.  Lung cancer. 9: Molecular biology of lung cancer: clinical implications.

Authors:  K M Fong; Y Sekido; A F Gazdar; J D Minna
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

Review 9.  Response of tumour cells to hypoxia: role of p53 and NFkB.

Authors:  J A Royds; S K Dower; E E Qwarnstrom; C E Lewis
Journal:  Mol Pathol       Date:  1998-04

10.  Prognostic significance of the combined score of endothelial expression of nucleolin and CD31 in surgically resected non-small cell lung cancer.

Authors:  Hongyun Zhao; Yan Huang; Cong Xue; Yang Chen; Xue Hou; Ying Guo; Liping Zhao; Zhi huang Hu; Yujie Huang; Yongzhang Luo; Li Zhang
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.